Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia

Progress in Neurobiology

Volumn 93, Issue 1, 2011, Pages 13-24

  Takahashi, Nagahide ^a   Sakurai, Takeshi ^a   Davis, Kenneth L ^a   Buxbaum, Joseph D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brain imaging; Dopamine; Gene expression; Genetic association; Glutamate; Myelin; Oligodendrocyte; Synaptic plasticity

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTAMIC ACID; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PHENCYCLIDINE; PROTEIN NOGO; PROTEIN TYROSINE PHOSPHATASE; PROTEOLIPID PROTEIN; TRANSFERRIN;

BRAIN REGION; COGNITION; COPY NUMBER VARIATION; DEMYELINATING DISEASE; DIFFUSION TENSOR IMAGING; DISEASE PREDISPOSITION; DRUG EFFECT; ELECTROENCEPHALOGRAM; FRACTIONAL ANISOTROPY; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MYELIN DEFICIENCY; NERVE CELL PLASTICITY; NERVE FIBER DEGENERATION; NERVE SPROUTING; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER; ANIMAL; CONGENITAL MALFORMATION; MYELIN SHEATH; NERVE CELL NETWORK; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; MYELIN SHEATH; NERVE NET; OLIGODENDROGLIA; SCHIZOPHRENIA;

EID: 78349265025     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2010.09.004     Document Type: Review

References (164)

1. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349:1730-1734.
2. Aston C., Jiang L., Sokolov B.P. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. Journal of Neuroscience Research 2004, 77:858-866.
3. Aston C., Jiang L., Sokolov B.P. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Molecular Psychiatry 2005, 10:309-322.
4. Balkowiec-Iskra E., Kurkowska-Jastrzebska I., Joniec I., Ciesielska A., Czlonkowska A., Czlonkowski A. Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration. Acta Neurobiologiae Experimentalis 2007, 67:379-388.
5. Balkowiec-Iskra E., Kurkowska-Jastrzebska I., Joniec I., Ciesielska A., Muszynska A., Przybylkowski A., et al. MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice. Inflammation Research 2007, 56:311-317.
6. Balkowiec-Iskra E., Kurkowska-Jastrzebska I., Joniec I., Czlonkowska A., Czlonkowski A. Post intoxicative therapeutic immunization with myelin oligodendrocyte glycoproteine (MOG 35-55) suppresses spontaneous regeneration of dopaminergic neurons injured with 1-methyl-4 phenyl-1,2,3,6-tetrahydropiridine (MPTP). Acta Neurobiologiae Experimentalis 2003, 63:109-115.
7. Balla A., Nattini M.E., Sershen H., Lajtha A., Dunlop D.S., Javitt D.C. GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum. Neuropharmacology 2009, 56:915-921.
8. Belachew S., Rogister B., Rigo J.M., Malgrange B., Moonen G. Neurotransmitter-mediated regulation of CNS myelination: a review. Acta Neurologica Belgica 1999, 99:21-31.
9. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neuroscience 2010, 13(1):76-83.
10. Benes F.M. Emerging principles of altered neural circuitry in schizophrenia. Brain Research Brain Research Reviews 2000, 31:251-269.
11. Bengtsson S.L., Nagy Z., Skare S., Forsman L., Forssberg H., Ullen F. Extensive piano practicing has regionally specific effects on white matter development. Nature Neuroscience 2005, 8(9):1148-1150.
12. Biancheri R., Zara F., Bruno C., Rossi A., Bordo L., Gazzerro E., et al. Phenotypic characterization of hypomyelination and congenital cataract. Annals of Neurology 2007, 62:121-127.
13. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. The Journal of Neuroscience 2007, 27:4519-4529.
14. Bjartmar C., Trapp B.D. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotoxicity Research 2003, 5:157-164.
15. Bongarzone E.R., Howard S.G., Schonmann V., Campagnoni A.T. Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. The Journal of Neuroscience 1998, 18:5344-5353.
16. Borodovsky N., Ponomaryov T., Frenkel S., Levkowitz G. Neural protein Olig2 acts upstream of the transcriptional regulator Sim1 to specify diencephalic dopaminergic neurons. Developmental Dynamics 2009, 238:826-834.
17. Brinkmann B.G., Agarwal A., Sereda M.W., Garratt A.N., Muller T., Wende H., et al. Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system. Neuron 2008, 59:581-595.
18. Budel S., Padukkavidana T., Liu B.P., Feng Z., Hu F., Johnson S., et al. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. The Journal of Neuroscience 2008, 28:13161-13172.
19. Buxbaum J.D., Georgieva L., Young J.J., Plescia C., Kajiwara Y., Jiang Y., et al. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Molecular Psychiatry 2008, 13:162-172.
20. Byne W., Tatusov A., Yiannoulos G., Vong G.S., Marcus S. Effects of mental illness and aging in two thalamic nuclei. Schizophrenia Research 2008, 106:172-181.
21. Calaora V., Rogister B., Bismuth K., Murray K., Brandt H., Leprince P., et al. Neuregulin signaling regulates neural precursor growth and the generation of oligodendrocytes in vitro. The Journal of Neuroscience 2001, 21:4740-4751.
22. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 2001, 41:237-260.
23. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. The Journal of Neuroscience 2009, 29:3442-3452.
24. Chen M.S., Huber A.B., van der Haar M.E., Frank M., Schnell L., Spillmann A.A., et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439.
25. Chen W., Gu N., Duan S., Sun Y., Zheng Y., Li C., et al. No association between the genetic polymorphisms within RTN4 and schizophrenia in the Chinese population. Neuroscience Letters 2004, 365:23-27.
26. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., Millar J.K. The DISC locus in psychiatric illness. Molecular Psychiatry 2008, 13:36-64.
27. Cianfoni A., Niku S., Imbesi S.G. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR American Journal of Neuroradiology 2007, 28:272-277.
28. Cocchi L., Walterfang M., Testa R., Wood S.J., Seal M.L., Suckling J., et al. Grey and white matter abnormalities are associated with impaired spatial working memory ability in first-episode schizophrenia. Schizophrenia Research 2009, 115:163-172.
29. Corfas G., Roy K., Buxbaum J.D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nature Neuroscience 2004, 7:575-580.
30. Covault J., Lee J., Jensen K., Kranzler H. Nogo 3'-untranslated region CAA insertion: failure to replicate association with schizophrenia and demonstration of marked population difference in frequency of the insertion. Brain Research Molecular Brain Research 2004, 120:197-200.
31. Daskalakis Z.J., Christensen B.K., Fitzgerald P.B., Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Archives of General Psychiatry 2008, 65:378-385.
32. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. The American Journal of Psychiatry 1991, 148:1474-1486.
33. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Archives of General Psychiatry 2003, 60:443-456.
34. de Chevigny A., Cooper O., Vinuela A., Reske-Nielsen C., Lagace D.C., Eisch A.J., et al. Fate mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells (Dayton, Ohio) 2008, 26:2349-2360.
35. De Gennaro L., Fratello F., Marzano C., Moroni F., Curcio G., Tempesta D., et al. Cortical plasticity induced by transcranial magnetic stimulation during wakefulness affects electroencephalogram activity during sleep. PloS One 2008, 3:e2483.
36. Defrin R., Pick C.G., Peretz C., Carmeli E. A quantitative somatosensory testing of pain threshold in individuals with mental retardation. Pain 2004, 108:58-66.
37. Denier C., Orgibet A., Roffi F., Jouvent E., Buhl C., Niel F., et al. Adult-onset vanishing white matter leukoencephalopathy presenting as psychosis. Neurology 2007, 68:1538-1539.
38. Dracheva S., Davis K.L., Chin B., Woo D.A., Schmeidler J., Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiology of Disease 2006, 21:531-540.
39. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Annals of Neurology 2006, 59:478-489.
40. el-Mallakh R.S., Pant B., Looney S.W. Nerve conduction velocity and H-reflex recovery in bipolar illness. The Journal of Neuropsychiatry and Clinical Neurosciences 1996, 8:412-416.
41. Fields R.D. Myelination: an overlooked mechanism of synaptic plasticity?. Neuroscientist 2005, 11:528-531.
42. Fields R.D. White matter in learning, cognition and psychiatric disorders. Trends in Neurosciences 2008, 31:361-370.
43. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Molecular Psychiatry 2003, 8:811-820.
44. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Molecular Psychiatry 2009.
45. Georgieva L., Moskvina V., Peirce T., Norton N., Bray N.J., Jones L., et al. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:12469-12474.
46. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotoxicity Research 2008, 14:71-78.
47. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. The American Journal of Psychiatry 2001, 158:1367-1377.
48. Gonzalez-Burgos G., Lewis D.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophrenia Bulletin 2008, 34:944-961.
49. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. The American Journal of Psychiatry 2003, 160:636-645.
50. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Research Brain Research Reviews 2000, 31:330-341.
51. GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403:439-444.
52. Gregg J.R., Herring N.R., Naydenov A.V., Hanlin R.P., Konradi C. Downregulation of oligodendrocyte transcripts is associated with impaired prefrontal cortex function in rats. Schizophrenia Research 2009, 113:277-287.
53. Gregorio S.P., Mury F.B., Ojopi E.B., Sallet P.C., Moreno D.H., Yacubian J., et al. Nogo CAA 3'UTR Insertion polymorphism is not associated with Schizophrenia nor with bipolar disorder. Schizophrenia Research 2005, 75:5-9.
54. Griffin J.W., Thompson W.J. Biology and pathology of nonmyelinating Schwann cells. Glia 2008, 56:1518-1531.
55. Hack M.A., Saghatelyan A., de Chevigny A., Pfeifer A., Ashery-Padan R., Lledo P.M., et al. Neuronal fate determinants of adult olfactory bulb neurogenesis. Nature Neuroscience 2005, 8:865-872.
56. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:4746-4751.
57. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry 2005, 10:40-68. (Image 45).
58. Harroch S., Furtado G.C., Brueck W., Rosenbluth J., Lafaille J., Chao M., et al. A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions. Nature Genetics 2002, 32:411-414.
59. Heimer L. Basal forebrain in the context of schizophrenia. Brain Research Brain Research Reviews 2000, 31:205-235.
60. Hof P.R., Haroutunian V., Friedrich V.L., Byne W., Buitron C., Perl D.P., et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biological Psychiatry 2003, 53:1075-1085.
61. Hoistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Frontiers in Neuroanatomy 2009, 3:9.
62. Hoke A., Ho T., Crawford T.O., LeBel C., Hilt D., Griffin J.W. Glial cell line-derived neurotrophic factor alters axon schwann cell units and promotes myelination in unmyelinated nerve fibers. The Journal of Neuroscience 2003, 23:561-567.
63. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
64. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 2009, 66:13-20.
65. Hsu R., Woodroffe A., Lai W.S., Cook M.N., Mukai J., Dunning J.P., et al. Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PloS One 2007, 2:e1234.
66. Hu X., Hicks C.W., He W., Wong P., Macklin W.B., Trapp B.D., et al. Bace1 modulates myelination in the central and peripheral nervous system. Nature Neuroscience 2006, 9:1520-1525.
67. Ikeda M., Aleksic B., Kirov G., Kinoshita Y., Yamanouchi Y., Kitajima T., et al. Copy number variation in schizophrenia in the Japanese population. Biological Psychiatry 2009, 67(3):283-286.
68. Inoue H., Lin L., Lee X., Shao Z., Mendes S., Snodgrass-Belt P., et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:14430-14435.
69. Jakovcevski I., Zecevic N. Olig transcription factors are expressed in oligodendrocyte and neuronal cells in human fetal CNS. The Journal of Neuroscience 2005, 25:10064-10073.
70. Joseph B., Dyer C.A. Relationship between myelin production and dopamine synthesis in the PKU mouse brain. Journal of Neurochemistry 2003, 86:615-626.
71. Juraska J.M., Kopcik J.R. Sex and environmental influences on the size and ultrastructure of the rat corpus callosum. Brain Research 1988, 450:1-8.
72. Kanaan R.A., Kim J.S., Kaufmann W.E., Pearlson G.D., Barker G.J., McGuire P.K. Diffusion tensor imaging in schizophrenia. Biological Psychiatry 2005, 58:921-929.
73. Katsel P., Davis K.L., Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophrenia Research 2005, 79:157-173.
74. Keefe R.S., Mohs R.C., Losonczy M.F., Davidson M., Silverman J.M., Kendler K.S., et al. Characteristics of very poor outcome schizophrenia. The American Journal of Psychiatry 1987, 144:889-895.
75. Kirov G., Grozeva D., Norton N., Ivanov D., Mantripragada K.K., Holmans P., et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Human Molecular Genetics 2009, 18:1497-1503.
76. Konopaske G.T., Dorph-Petersen K.A., Sweet R.A., Pierri J.N., Zhang W., Sampson A.R., et al. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry 2008, 63:759-765.
77. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., et al. A review of diffusion tensor imaging studies in schizophrenia. Journal of Psychiatric Research 2007, 41:15-30.
78. Kurkowska-Jastrzebska I., Balkowiec-Iskra E., Joniec I., Litwin T., Czlonkowski A., Czlonkowska A. Immunization with myelin oligodendrocyte glycoprotein and complete Freund adjuvant partially protects dopaminergic neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage in mouse model of Parkinson's disease. Neuroscience 2005, 131:247-254.
79. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. The Journal of Neuroscience 2005, 25:11693-11709.
80. Lee H., Raiker S.J., Venkatesh K., Geary R., Robak L.A., Zhang Y., et al. Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. The Journal of Neuroscience 2008, 28:2753-2765.
81. Li B., Woo R.S., Mei L., Malinow R. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron 2007, 54:583-597.
82. Liddle P.F. Functional imaging - schizophrenia. British Medical Bulletin 1996, 52:486-494.
83. Lim K.O., Ardekani B.A., Nierenberg J., Butler P.D., Javitt D.C., Hoptman M.J. Voxelwise correlational analyses of white matter integrity in multiple cognitive domains in schizophrenia. The American Journal of Psychiatry 2006, 163:2008-2010.
84. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science (New York, NY) 1993, 260:1130-1132.
85. Lindahl J.S., Kjellsen B.R., Tigert J., Miskimins R. In utero PCP exposure alters oligodendrocyte differentiation and myelination in developing rat frontal cortex. Brain Research 2008, 1234:137-147.
86. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. American Journal of Human Genetics 2001, 69:96-105.
87. Liu X., Qin W., He G., Yang Y., Chen Q., Zhou J., et al. A family-based association study of the MOG gene with schizophrenia in the Chinese population. Schizophrenia Research 2005, 73:275-280.
88. Lorenzetti D., Antalffy B., Vogel H., Noveroske J., Armstrong D., Justice M. The neurological mutant quaking(viable) is Parkin deficient. Mamm Genome 2004, 15:210-217.
89. Lu Z., Zhang Y., Ku L., Wang H., Ahmadian A., Feng Y. The quakingviable mutation affects qkI mRNA expression specifically in myelin-producing cells of the nervous system. Nucleic Acids Research 2003, 31:4616-4624.
90. Maeno N., Takahashi N., Saito S., Ji X., Ishihara R., Aoyama N., et al. Association of SOX10 with schizophrenia in the Japanese population. Psychiatric genetics 2007, 17(4):227-231.
91. Makinodan M., Tatsumi K., Okuda H., Manabe T., Yamauchi T., Noriyama Y., et al. Lysophosphatidylcholine induces delayed myelination in the juvenile ventral hippocampus and behavioral alterations in adulthood. Neurochemistry International 2008, 53:374-381.
92. Makinodan M., Yamauchi T., Tatsumi K., Okuda H., Takeda T., Kiuchi K., et al. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Progress in Neuro-psychopharmacology & Biological Psychiatry 2009, 33:978-985.
93. McClure R.J., Keshavan M.S., Pettegrew J.W. Chemical and physiologic brain imaging in schizophrenia. The Psychiatric Clinics of North America 1998, 21:93-122.
94. McGee A.W., Yang Y., Fischer Q.S., Daw N.W., Strittmatter S.M. Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science (New York, NY) 2005, 309(5744):2222-2226.
95. McKerracher L., David S., Jackson D.L., Kottis V., Dunn R.J., Braun P.E. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994, 13:805-811.
96. Mi S., Lee X., Shao Z., Thill G., Ji B., Relton J., et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nature Neuroscience 2004, 7:221-228.
97. Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nature Neuroscience 2005, 8:745-751.
98. Michelato A., Bonvicini C., Ventriglia M., Scassellati C., Randazzo R., Bignotti S., et al. 3' UTR (AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neuroscience Letters 2004, 357:235-237.
99. Middleton F.A., Strick P.L. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Research Brain Research Reviews 2000, 31:236-250.
100. Millar J.K., Wilson-Annan J.C., Anderson S., Christie S., Taylor M.S., Semple C.A., et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Human Molecular Genetics 2000, 9:1415-1423.
101. Mitelman S.A., Buchsbaum M.S. Very poor outcome schizophrenia: clinical and neuroimaging aspects. International Review of Psychiatry (Abingdon, England) 2007, 19:345-357.
102. Mitkus S.N., Hyde T.M., Vakkalanka R., Kolachana B., Weinberger D.R., Kleinman J.E., et al. Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophrenia Research 2008, 98:129-138.
103. Morishita H., Hensch T.K. Critical period revisited: impact on vision. Current Opinion in Neurobiology 2008, 18(1):101-107.
104. Narayan S., Kass K.E., Thomas E.A. Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. Journal of Neuroscience Research 2007, 85:757-765.
105. Nestor P.G., Kubicki M., Gurrera R.J., Niznikiewicz M., Frumin M., McCarley R.W., et al. Neuropsychological correlates of diffusion tensor imaging in schizophrenia. Neuropsychology 2004, 18:629-637.
106. Newcombe J., Uddin A., Dove R., Patel B., Turski L., Nishizawa Y., et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathology (Zurich, Switzerland) 2008, 18:52-61.
107. Niisato K., Fujikawa A., Komai S., Shintani T., Watanabe E., Sakaguchi G., et al. Age-dependent enhancement of hippocampal long-term potentiation and impairment of spatial learning through the Rho-associated kinase pathway in protein tyrosine phosphatase receptor type Z-deficient mice. The Journal of Neuroscience 2005, 25:1081-1088.
108. Nikulina E.M., Skrinskaya J.A., Avgustinovich D.F., Popova N.K. Dopaminergic brain system in the quaking mutant mouse. Pharmacology, Biochemistry, and Behavior 1995, 50:333-337.
109. Norton N., Moskvina V., Morris D.W., Bray N.J., Zammit S., Williams N.M., et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2006, 141B:96-101.
110. Novak G., Kim D., Seeman P., Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Research Molecular Brain Research 2002, 107:183-189.
111. Ohsawa Y., Murakami T., Miyazaki Y., Shirabe T., Sunada Y. Peripheral myelin protein 22 is expressed in human central nervous system. Journal of the Neurological Sciences 2006, 247:11-15.
112. Peirce T.R., Bray N.J., Williams N.M., Norton N., Moskvina V., Preece A., et al. Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Archives of General Psychiatry 2006, 63:18-24.
113. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine 2000, 6:67-70.
114. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular Psychiatry 2004, 9:684-697. 643.
115. Qin W., Gao J., Xing Q., Yang J., Qian X., Li X., et al. A family-based association study of PLP1 and schizophrenia. Neuroscience Letters 2005, 375:207-210.
116. Qu M., Yue W., Tang F., Wang L., Han Y., Zhang D. Polymorphisms of transferrin gene are associated with schizophrenia in Chinese Han population. Journal of Psychiatric Research 2008, 42:877-883.
117. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry 2005, 10:434-449.
118. Ross S.E., Greenberg M.E., Stiles C.D. Basic helix-loop-helix factors in cortical development. Neuron 2003, 39:13-25.
119. Rowitch D.H., Lu Q.R., Kessaris N., Richardson W.D. An 'oligarchy' rules neural development. Trends in Neurosciences 2002, 25:417-422.
120. Roy K., Murtie J.C., El-Khodor B.F., Edgar N., Sardi S.P., Hooks B.M., et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8131-8136.
121. Safferman A.Z., Kane J.M., Aronowitz J.S., Gordon M.F., Pollack S., Lieberman J.A. The use of clozapine in neurologic disorders. The Journal of Clinical Psychiatry 1994, 55(Suppl. B):98-101.
122. Sarchielli P., Greco L., Floridi A., Floridi A., Gallai V. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Archives of Neurology 2003, 60:1082-1088.
123. Sauvageot C.M., Stiles C.D. Molecular mechanisms controlling cortical gliogenesis. Current Opinion in Neurobiology 2002, 12:244-249.
124. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5585-5590.
125. Sinibaldi L., De Luca A., Bellacchio E., Conti E., Pasini A., Paloscia C., et al. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Human Mutation 2004, 24:534-535.
126. Soontarapornchai K., Maselli R., Fenton-Farrell G., Tassone F., Hagerman P.J., Hessl D., et al. Abnormal nerve conduction features in fragile X premutation carriers. Archives of Neurology 2008, 65:495-498.
127. Stark A.K., Uylings H.B., Sanz-Arigita E., Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. The American Journal of Psychiatry 2004, 161:882-888.
128. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. The British Journal of Psychiatry 2006, 188:510-518.
129. Stefansson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. American Journal of Human Genetics 2003, 72:83-87.
130. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics 2002, 71:877-892.
131. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biological Psychiatry 2006, 59:929-939.
132. Stephan K.E., Friston K.J., Frith C.D. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophrenia Bulletin 2009, 35:509-527.
133. Sussman C.R., Vartanian T., Miller R.H. The ErbB4 neuregulin receptor mediates suppression of oligodendrocyte maturation. The Journal of Neuroscience 2005, 25:5757-5762.
134. Syken J., Grandpre T., Kanold P.O., Shatz C.J. PirB restricts ocular-dominance plasticity in visual cortex. Science (New York, NY) 2006, 313(5794):1795-1800.
135. Szeligo F., Leblond C.P. Response of the three main types of glial cells of cortex and corpus callosum in rats handled during suckling or exposed to enriched, control and impoverished environments following weaning. The Journal of Comparative Neurology 1977, 172:247-263.
136. Tackenberg B., Moller J.C., Rindock H., Bien S., Sommer N., Oertel W.H., et al. CNS involvement in hereditary neuropathy with pressure palsies (HNPP). Neurology 2006, 67:2250-2252.
137. Tamminga C.A., Holcomb H.H. Phenotype of schizophrenia: a review and formulation. Molecular Psychiatry 2005, 10:27-39.
138. Tan E.C., Chong S.A., Wang H., Chew-Ping Lim E., Teo Y.Y. Gender-specific association of insertion/deletion polymorphisms in the nogo gene and chronic schizophrenia. Brain Research Molecular Brain Research 2005, 139:212-216.
139. Tan H.Y., Callicott J.H., Weinberger D.R. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cognitive Neuropsychiatry 2009, 14:277-298.
140. Tanaka H., Ma J., Tanaka K.F., Takao K., Komada M., Tanda K., et al. Mice with altered myelin proteolipid protein gene expression display cognitive deficits accompanied by abnormal neuron-glia interactions and decreased conduction velocities. The Journal of Neuroscience 2009, 29:8363-8371.
141. Taveggia C., Thaker P., Petrylak A., Caporaso G.L., Toews A., Falls D.L., et al. Type III neuregulin-1 promotes oligodendrocyte myelination. Glia 2008, 56:284-293.
142. Thaker G.K. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophrenia Bulletin 2008, 34:760-773.
143. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
144. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Research Bulletin 2001, 55:597-610.
145. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., Rachmanova V.I. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophrenia Research 2004, 67:269-275.
146. Vallejo-Illarramendi A., Domercq M., Perez-Cerda F., Ravid R., Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiology of Disease 2006, 21:154-164.
147. Voineskos A.N. Converging evidence for the Nogo-66 receptor gene in schizophrenia. The Journal of Neuroscience 2009, 29:5045-5047.
148. Walsh T., McClellan J.M., McCarthy S.E., Addington A.M., Pierce S.B., Cooper G.M., et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (New York, NY) 2008, 320:539-543.
149. Walterfang M., Wood S.J., Velakoulis D., Copolov D., Pantelis C. Diseases of white matter and schizophrenia-like psychosis. The Australian and New Zealand Journal of Psychiatry 2005, 39:746-756.
150. Wan C., Yang Y., Feng G., Gu N., Liu H., Zhu S., et al. Polymorphisms of myelin-associated glycoprotein gene are associated with schizophrenia in the Chinese Han population. Neuroscience Letters 2005, 388:126-131.
151. Wang H., Song L., Laird F., Wong P.C., Lee H.K. BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. The Journal of Neuroscience 2008, 28:8677-8681.
152. Wang K.C., Koprivica V., Kim J.A., Sivasankaran R., Guo Y., Neve R.L., et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944.
153. Wiendl H., Toyka K.V., Rieckmann P., Gold R., Hartung H.P., Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. Journal of Neurology 2008, 255:1449-1463.
154. Wilkins A., Majed H., Layfield R., Compston A., Chandran S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. The Journal of Neuroscience 2003, 23:4967-4974.
155. Williams N.M., Preece A., Spurlock G., Norton N., Williams H.J., Zammit S., et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Molecular Psychiatry 2003, 8:485-487.
156. Witthaus H., Brune M., Kaufmann C., Bohner G., Ozgurdal S., Gudlowski Y., et al. White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophrenia Research 2008, 102:141-149.
157. Wood J.D., Bonath F., Kumar S., Ross C.A., Cunliffe V.T. Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Human Molecular Genetics 2009, 18:391-404.
158. Xi Z.R., Qin W., Yang Y.F., He G., Gao S.H., Ren M.S., et al. Transmission disequilibrium analysis of the GSN gene in a cohort of family trios with schizophrenia. Neuroscience Letters 2004, 372:200-203.
159. Xiao L., Xu H., Zhang Y., Wei Z., He J., Jiang W., et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Molecular Psychiatry 2008, 13:697-708.
160. Xiong L., Rouleau G.A., Delisi L.E., St-Onge J., Najafee R., Riviere J.B., et al. CAA insertion polymorphism in the 3'UTR of Nogo gene on 2p14 is not associated with schizophrenia. Brain Research Molecular Brain Research 2005, 133:153-156.
161. Xu H., Yang H.J., Zhang Y., Clough R., Browning R., Li X.M. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behavioral Neuroscience 2009, 123:418-429.
162. Yamazaki Y., Hozumi Y., Kaneko K., Sugihara T., Fujii S., Goto K., et al. Modulatory effects of oligodendrocytes on the conduction velocity of action potentials along axons in the alveus of the rat hippocampal CA1 region. Neuron Glia Biology 2007, 3:325-334.
163. Yang Y.F., Qin W., Shugart Y.Y., He G., Liu X.M., Zhou J., et al. Possible association of the MAG locus with schizophrenia in a Chinese Han cohort of family trios. Schizophrenia Research 2005, 75:11-19.
164. Zhao X.H., Jin W.L., Wu J., Mi S., Ju G. Inactivation of glycogen synthase kinase-3beta and up-regulation of LINGO-1 are involved in LINGO-1 antagonist regulated survival of cerebellar granular neurons. Cellular and Molecular Neurobiology 2008, 28:727-735.